Latest news with #CORT
Yahoo
6 days ago
- Business
- Yahoo
Corcept: Q1 Earnings Snapshot
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Corcept Therapeutics Inc. (CORT) on Monday reported first-quarter net income of $20.3 million. The Redwood City, California-based company said it had net income of 17 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for earnings of 17 cents per share. The drug developer posted revenue of $157.2 million in the period, missing Street forecasts. Four analysts surveyed by Zacks expected $178 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on CORT at Sign in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Corcept Therapeutics Incorporated CORT reported first-quarter 2025 earnings of 17 cents per share, which were in line with the Zacks Consensus Estimate. The company had reported earnings of 25 cents per share in the year-ago quarter. Revenues in the first quarter increased 7.1% year over year to $157.2 million. The figure, however, missed the Zacks Consensus Estimate of $178 million. The top line solely comprises product sales of the Cushing's syndrome drug, Korlym. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Year to date, shares of Corcept have rallied 46.8% against the industry's decline of 0.4%. Image Source: Zacks Investment Research Revenues from Korlym also missed our model estimate of $179.1 million. Per management, Korlym sales in the first quarter were affected by the insufficient capacity of a specialty pharmacy vendor who was unable to fulfill the surge in demand. The lower-than-expected sales disappointed investors. Consequently, shares of CORT were down 7.5% in after-hours trading on May 5 following the earnings result announcement. Research and development expenses rose 3.8% year over year to $60.7 million. Selling, general and administrative expenses increased around 61.1% year over year to $90.7 million. Consequently, operating expenses increased 31.1% year over year to $153.8 million in the first quarter. Cash and investments, as of March 31, 2025, totaled $570.8 million compared with $603.2 million as of Dec. 31, 2024. Corcept reiterated its total revenue guidance for 2025. The company continues to expect total revenues in the range of $900-$950 million in 2025. The Zacks Consensus Estimate for revenues is pegged at $905.7 million. Corcept is developing its lead candidate, relacorilant, for treating patients with Cushing's syndrome. In December 2024, CORT submitted a new drug application (NDA) for relacorilant to the FDA for the same. The NDA was based on positive data from the GRACE study and confirmatory evidence from the phase III GRADIENT, as well as long-term extension studies and a phase II study in hypercortisolism. In March 2025, the FDA accepted the NDA and assigned a Prescription Drug User Fee Act target action date of Dec. 30, 2025. Corcept is also evaluating relacorilant in combination studies for treating different types of cancer indications. The phase III ROSELLA study, which evaluated relacorilant in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival (PFS). Corcept plans to submit a new drug application in the United States in the third quarter of 2025, while a marketing authorization application in Europe is likely to be filed shortly thereafter. Last month, Corcept initiated the phase II BELLA study evaluating relacorilant plus nab-paclitaxel and Roche's RHHBY Avastin (bevacizumab) for treating patients with platinum-resistant ovarian cancer. Per management, the BELLA study will help in understanding whether combining relacorilant with two medicines — nab-paclitaxel and RHHBY's Avastin — offers patients an additional treatment option or not. The company is also evaluating relacorilant plus Xtandi (enzalutamide) in patients with early-stage prostate cancer. The study is being conducted in collaboration with the University of Chicago. In December 2024, Corcept announced data from the phase II DAZALS study, which evaluated its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis (ALS), a degenerative neurologic disorder. The study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients treated with dazucorilant versus those treated with placebo. However, an exploratory analysis of the DAZALS study at the one-year mark showed that patients who were treated with dazucorilant (300 mg) at baseline demonstrated significantly improved overall survival, compared to patients who received a placebo. Patients then did not switch to dazucorilant in the long-term extension study. Corcept is looking to seek input from the FDA and the European regulatory body to discuss the next steps of development for dazucorilant. Corcept Therapeutics Incorporated price-consensus-eps-surprise-chart | Corcept Therapeutics Incorporated Quote Corcept currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are ADMA Biologics Inc. ADMA and Immunocore Holdings PLC IMCR, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for ADMA Biologics' earnings per share have increased from 69 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 38.3%. ADMA's earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%. In the past 60 days, estimates for Immunocore's loss per share have narrowed from $1.63 to $1.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.83 to $1.68. Year to date, shares of IMCR have gained 3.9%. IMCR's earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 31.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-04-2025
- Business
- Yahoo
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
Corcept Therapeutics (CORT) shares rallied 109.1% in the last trading session to close at $114.22. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 9.8% loss over the past four weeks. The stock surged after company announced data from the phase III ROSELLA study, which evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer. The ROSELLA study met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review. This drug developer is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of -32%. Revenues are expected to be $177.97 million, up 21.2% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For Corcept, the consensus EPS estimate for the quarter has been revised 53.1% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on CORT going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Corcept is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Ironwood Pharmaceuticals (IRWD), finished the last trading session 4.3% higher at $1.47. IRWD has returned -12.4% over the past month. Ironwood's consensus EPS estimate for the upcoming report has changed -800% over the past month to -$0.02. Compared to the company's year-ago EPS, this represents no change. Ironwood currently boasts a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
02-04-2025
- Business
- Yahoo
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
Shares of Corcept Therapeutics Incorporated CORT were up a staggering 109.1% on March 31 after the company announced data from the phase III ROSELLA study, which evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer. The ROSELLA study met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR). Per management, data from the ROSELLA study suggested that the combo of relacorilant plus nab-paclitaxel has the potential to become a new standard of care for patients with platinum-resistant ovarian cancer. Year to date, shares of Corcept have skyrocketed 126.7% against the industry's decline of 1.9%. Image Source: Zacks Investment Research The phase III ROSELLA study evaluated relacorilant in combination with nab-paclitaxel for treating patients with recurrent, platinum-resistant ovarian cancer. Data from the same showed that treatment with relacorilant plus nab-paclitaxel reduced the risk of disease progression by 30% compared to patients treated with nab-paclitaxel alone. Patients who were treated with relacorilant plus nab-paclitaxel achieved a median PFS-BICR of 6.5 months compared to 5.5 months in patients who received nab-paclitaxel alone. Patients treated with the combo of relacorilant plus nab-paclitaxel had a significant improvement in overall survival (OS), with the median OS being 16 months versus 11.5 months for patients receiving nab-paclitaxel alone, at an interim analysis of OS. The combo of relacorilant plus nab-paclitaxel improved progression-free and overall survival without increasing the side effect burden. The company plans to submit a new drug application in the United States in the third quarter of 2025, while a marketing authorization application in Europe is likely to be filed shortly thereafter. Relacorilant is Corcept's lead candidate, which is being developed for treating patients with Cushing's syndrome. In December 2024, CORT submitted a new drug application (NDA) for relacorilant to the FDA for the same. Last month, the FDA accepted the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of Dec. 30, 2025. The NDA was based on positive data from the GRACE study and confirmatory evidence from the phase III GRADIENT, as well as long-term extension studies and a phase II study in hypercortisolism. Another study is evaluating relacorilant in combination with Keytruda (pembrolizumab) for treating patients with adrenal cancer along with cortisol excess. The successful development and commercialization of relacorilant for additional indications will be a big boost to the company. Corcept currently carries a Zacks Rank #2 (Buy). Some top-ranked stocks in the biotech sector are Amicus Therapeutics, Inc. FOLD, CytomX Therapeutics, Inc. CTMX and ANI Pharmaceuticals, Inc. ANIP, each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, estimates for Amicus' earnings per share have increased from 43 cents to 52 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 72 cents to 78 cents. Year to date, shares of FOLD have declined 13.4%. FOLD's earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 45.42% In the past 60 days, estimates for CytomX Therapeutics have improved from a loss of 31 cents per share to earnings of 25 cents per share. During the same time, loss per share estimates for 2026 have narrowed from 65 cents to 31 cents. Year to date, shares of CTMX have plunged 38.2%. CTMX's earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 180.70%. In the past 60 days, estimates for ANI Pharmaceuticals' earnings per share have increased from $5.54 to $6.35 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.75 to $7.21. Year to date, shares of ANIP have rallied 21.2%. ANIP's earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
01-04-2025
- Business
- Yahoo
Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?
We recently published a list of . In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other firms that kicked off the trading week stronger. The stock market began the trading week on a mixed note as investors continued to digest President Donald Trump's new tariff agenda, with all economies expecting to be hit by import taxes. Among all major indices, only the Nasdaq registered losses, down 0.14 percent. In contrast, the Dow Jones jumped by 1 percent while the S&P 500 grew by 0.55 percent. Despite the broader market downturn, 10 individual stocks stood their ground, finishing the day in the green amid a flurry of fresh corporate developments that boosted investor appetite. In this article, we named Monday's top performers and detailed the reasons behind their gains. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. Corcept Therapeutics soared by 109.08 percent on Monday to end at $114.22 apiece as investors cheered impressive results of its phase 3 trial for ovarian cancer treatment. According to the company, the trial met its primary endpoint for its ROSELLA treatment, having seen a 30-percent reduction in the risk of disease progression to patients treated with relacorilant in addition to nab-paclitaxel chemotherapy. 'The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,' said CORT Chief Development Officer Bill Guyer. 'We deeply appreciate the patients and investigators who participated in the trial, and we look forward to presenting the trial's full results in the coming months.' CORT said it expects to submit a new drug application in the third quarter of the year. Overall, CORT ranks 1st on our list of firms that kicked off the trading week stronger. While we acknowledge the potential of CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as CORT but trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
